These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20564336)

  • 1. Relative bioavailability of three different solid forms of PNU-141659 as determined with the artificial stomach-duodenum model.
    Carino SR; Sperry DC; Hawley M
    J Pharm Sci; 2010 Sep; 99(9):3923-30. PubMed ID: 20564336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism for enhanced absorption of a solid dispersion formulation of LY2300559 using the artificial stomach duodenum model.
    Polster CS; Wu SJ; Gueorguieva I; Sperry DC
    Mol Pharm; 2015 Apr; 12(4):1131-40. PubMed ID: 25723790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of an Artificial Stomach-Duodenum Reduced Gastric pH Dog Model for Formulation Principle Assessment and Mechanistic Performance Understanding.
    Lee CM; Luner PE; Locke K; Briggs K
    J Pharm Sci; 2017 Aug; 106(8):1987-1997. PubMed ID: 28238897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative bioavailability estimation of carbamazepine crystal forms using an artificial stomach-duodenum model.
    Carino SR; Sperry DC; Hawley M
    J Pharm Sci; 2006 Jan; 95(1):116-25. PubMed ID: 16315223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative Bioavailability Assessment of Solid Forms by An Artificial Stomach and Duodenum Apparatus.
    Guo Y; Byer-Alcorace A; Thomas C; Piekos S; Luo L; Hawley M; Sun CC
    J Pharm Sci; 2024 Aug; 113(8):2506-2512. PubMed ID: 38768754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amorphous Solid Dispersions: Utilization and Challenges in Drug Discovery and Development.
    He Y; Ho C
    J Pharm Sci; 2015 Oct; 104(10):3237-58. PubMed ID: 26175316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solution-mediated phase transformation: significance during dissolution and implications for bioavailability.
    Greco K; Bogner R
    J Pharm Sci; 2012 Sep; 101(9):2996-3018. PubMed ID: 22213419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.
    Qian F; Huang J; Hussain MA
    J Pharm Sci; 2010 Jul; 99(7):2941-7. PubMed ID: 20127825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and dynamic properties of amorphous solid dispersions: the role of solid-state nuclear magnetic resonance spectroscopy and relaxometry.
    Paudel A; Geppi M; Mooter GVD
    J Pharm Sci; 2014 Sep; 103(9):2635-2662. PubMed ID: 24715618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    J Pharm Sci; 2010 Mar; 99(3):1254-64. PubMed ID: 19697391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amorphous solid dispersions: a robust platform to address bioavailability challenges.
    Newman A; Nagapudi K; Wenslow R
    Ther Deliv; 2015 Feb; 6(2):247-61. PubMed ID: 25690090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging trends in the stabilization of amorphous drugs.
    Laitinen R; Löbmann K; Strachan CJ; Grohganz H; Rades T
    Int J Pharm; 2013 Aug; 453(1):65-79. PubMed ID: 22569230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of gastric pH on the pharmacokinetics of a BCS class II compound in dogs: utilization of an artificial stomach and duodenum dissolution model and GastroPlus,™ simulations to predict absorption.
    Bhattachar SN; Perkins EJ; Tan JS; Burns LJ
    J Pharm Sci; 2011 Nov; 100(11):4756-65. PubMed ID: 21681753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic in vitro and in vivo evaluation for determining the feasibility of making an amorphous solid dispersion of a B-Raf (rapidly accelerated fibrosarcoma) inhibitor.
    Cui Y; Chiang PC; Choo EF; Boggs J; Rudolph J; Grina J; Wenglowsky S; Ran Y
    Int J Pharm; 2013 Sep; 454(1):241-8. PubMed ID: 23834830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The polymorphism of statins and its effect on their physicochemical properties.
    Karaźniewicz-Łada M; Bąba K; Dolatowski F; Dobrowolska A; Rakicka M
    Polim Med; 2018; 48(2):77-82. PubMed ID: 30916495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Polymorph transformation of solid drugs].
    Zhang Q; Mei XF
    Yao Xue Xue Bao; 2015 May; 50(5):521-7. PubMed ID: 26234130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the true solubility advantage for amorphous pharmaceuticals?
    Hancock BC; Parks M
    Pharm Res; 2000 Apr; 17(4):397-404. PubMed ID: 10870982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of supersaturation of amorphous pharmaceuticals: nonlinear rate of supersaturation generation regulated by matrix diffusion.
    Sun DD; Lee PI
    Mol Pharm; 2015 Apr; 12(4):1203-15. PubMed ID: 25775257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.